ReviewBiotechnology journal2008
Novel human antibody therapeutics: the age of the Umabs.
Review in Biotechnology journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Therapeutic drug monitoring of biologics in psoriasis.Biologics : targets & therapy · 2019Review
- Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.Frontiers in immunology · 2019Article
- The Immunogenetics of Psoriasis and Implications for Drug Repositioning.International journal of molecular sciences · 2017Review
- Molecular dynamics simulation of the crystallizable fragment of IgG1-insights for the design of Fcabs.International journal of molecular sciences · 2014Article
- Of mice and men: the need for humanized mouse models to study human IgG activity in vivo.Journal of clinical immunology · 2013Review
- The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy.British journal of cancer · 2009Review
- Interaction of antibodies with ErbB receptor extracellular regions.Experimental cell research · 2009Review
- Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.mAbsArticle
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies represent a major and increasingly important category of biotechnology products for the treatment of human diseases. The state-of-the-art of antibody technology has evolved to the point where therapeutic monoclonal antibodies, that are practically indistinguishable from antibodies induced in humans, are routinely generated. We depict how our science-based approach can be used to further improve the efficacy of antibody therapeutics, illustrated by the development of three monoclonal antibodies for various cancer indications: zanolimumab (directed against CD4), ofatumumab (directed against CD20) and zalutumumab (directed against epidermal growth factor receptor).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.